Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;54(2):e2250340.
doi: 10.1002/eji.202250340. Epub 2023 Dec 3.

Antibodies internalization mechanisms by dendritic cells and their role in therapeutic antibody immunogenicity

Affiliations
Free article
Review

Antibodies internalization mechanisms by dendritic cells and their role in therapeutic antibody immunogenicity

Maria Lteif et al. Eur J Immunol. 2024 Feb.
Free article

Abstract

Internalization and processing by antigen-presenting cells such as dendritic cells (DCs) are critical steps for initiating a T-cell response to therapeutic antibodies. Consequences are the production of neutralizing antidrug antibodies altering the clinical response, the presence of immune complexes, and, in some rare cases, hypersensitivity reactions. In recent years, significant progress has been made in the knowledge of cellular uptake mechanisms of antibodies in DCs. The uptake of antibodies could be directly related to their immunogenicity by regulating the quantity of materials entering the DCs in relation to antibody structure. Here, we summarize the latest insights into cellular uptake mechanisms and pathways in DCs. We highlight the approaches to study endocytosis, the impact of endocytosis routes on T-cell response, and discuss the link between how DCs internalize therapeutic antibodies and the potential mechanisms that could give rise to immunogenicity. Understanding these processes could help in developing assays to evaluate the immunogenicity potential of biotherapeutics.

Keywords: Dendritic cells; Immunogenicity; Internalization; Therapeutic Antibodies.

PubMed Disclaimer

References

    1. Dingman, R. and Balu-Iyer, S. V., Immunogenicity of protein pharmaceuticals. J. Pharm. Sci. 2019. 108: 1637-1654.
    1. Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., Prignano, F. et al., Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin. Exp. Immunol. 2016. 186: 364-372.
    1. Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., Topp, E. M. et al., Immunogenicity of therapeutic protein aggregates. J. Pharm. Sci. 2016. 105: 417-430.
    1. Jawa, V., Terry, F., Gokemeijer, J., Mitra-Kaushik, S., Roberts, B. J., Tourdot, S. and De Groot, A. S., T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated consensus and review 2020. Front. Immunol. 2020. 11: 1301.
    1. Tai, Y., Wang, Q., Korner, H., Zhang, L. and Wei, W., Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front. Pharmacol. 2018. 9: 642.

LinkOut - more resources